AGP Picks
View all

Today's News: Middle East
Provided by AGP

Today's News: Middle East: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today's News: Middle East.

August 2026

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31

September 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30

October 2026

Mo Tu We Th Fr Sa Su
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31

Press releases published on October 14, 2026

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
Oct. 14, 2026

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study

Indeterminate GlobeNewswire
Orvida Pharma Announces FDA Acceptance of KM-023 (ontivatrep) into Rare Disease Evidence Principles Process for Olmsted Syndrome
Oct. 14, 2026

Orvida Pharma Announces FDA Acceptance of KM-023 (ontivatrep) into Rare Disease Evidence Principles Process for Olmsted Syndrome

Indeterminate GlobeNewswire
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
Oct. 14, 2026

Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45

Indeterminate GlobeNewswire
Arexera Therapeutics, Formerly Atalanta Therapeutics, Unveils New Corporate Identity and Advances Huntington's Disease Franchise
Oct. 14, 2026

Arexera Therapeutics, Formerly Atalanta Therapeutics, Unveils New Corporate Identity and Advances Huntington's Disease Franchise

Indeterminate GlobeNewswire
Elion Therapeutics Expands Pipeline with Exclusive Global License to Inhaled Antifungal for Immunocompromised Patients
Oct. 14, 2026

Elion Therapeutics Expands Pipeline with Exclusive Global License to Inhaled Antifungal for Immunocompromised Patients

Indeterminate GlobeNewswire
Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis
Oct. 14, 2026

Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis

Indeterminate GlobeNewswire
Aya Gold & Silver Reports Record Q3-2026 Production of 2.03 Million AgEq Ounces
Oct. 14, 2026

Aya Gold & Silver Reports Record Q3-2026 Production of 2.03 Million AgEq Ounces

Indeterminate GlobeNewswire
Middle East Stablecoin Association Partners with Luna PR to Shape the Future of Digital Finance in the Region
Oct. 14, 2026

Middle East Stablecoin Association Partners with Luna PR to Shape the Future of Digital Finance in the Region

Indeterminate GlobeNewswire
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome
Oct. 14, 2026

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Indeterminate GlobeNewswire
Rakovina Therapeutics Secures Exclusivity on Optimized kt-5000 Lead Profile from Variational AI
Oct. 14, 2026

Rakovina Therapeutics Secures Exclusivity on Optimized kt-5000 Lead Profile from Variational AI

Indeterminate GlobeNewswire
Friendly Technologies Showcases Faster AI-Assisted Wi-Fi Problem Resolution at Network X, October 13–15, 2026
Oct. 14, 2026

Friendly Technologies Showcases Faster AI-Assisted Wi-Fi Problem Resolution at Network X, October 13–15, 2026

Indeterminate GlobeNewswire
Classiq and FreeYa Mind Campus Partner to Establish a Quantum Applications Hub in Romania
Oct. 14, 2026

Classiq and FreeYa Mind Campus Partner to Establish a Quantum Applications Hub in Romania

Indeterminate GlobeNewswire
Nxera Pharma Enters into Exclusive License, Supply and Commercialization Agreement with Synmosa for QUVIVIQ® (daridorexant) Across Eight Asia-Pacific Markets
Oct. 14, 2026

Nxera Pharma Enters into Exclusive License, Supply and Commercialization Agreement with Synmosa for QUVIVIQ® (daridorexant) Across Eight Asia-Pacific Markets

Indeterminate GlobeNewswire
Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026
Oct. 14, 2026

Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026

Indeterminate GlobeNewswire

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Today's News: Middle East

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.